Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (NASDAQ: TTPH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Tetraphase securities: 1) pursuant and/or traceable to its registration statement and prospectus issued in connection with the its July 2017
NEW YORK, July 30, 2018 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against TetraPhase Pharmaceuticals (“Tetraphase” or the “Company”) (NASDAQ: TTPH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Tetraphase securities: 1) pursuant and/or traceable to its registration statement and prospectus issued in connection with the its July 2017 secondary public offering (“SPO” or the “Offering”); and/or, 2) acquired Tetraphase securities between March 8, 2017 and February 13, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/ttph.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Act of 1933 (the “Securities Act”) and the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial’s primary endpoints (within the 10% non-inferiority margin); (2) The enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial’s primary endpoints; and (3) consequently, Defendants’ statements about Tetraphase’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/ttph or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Tetraphase you have until September 25, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert---bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-tetraphase-pharmaceuticals-inc-ttph-and-lead-plaintiff-deadline--september-25-2018-300688268.html
SOURCE Bronstein, Gewirtz & Grossman, LLC
Company Codes: NASDAQ-NMS:TTPH
